MacroGenics Divests Manufacturing, Extends Cash Runway to 2028 after $20.8M Q1 Revenues
MacroGenics is divesting its manufacturing operations to Bora Pharmaceuticals to focus on core drug development, extending its cash runway through 2028. In Q1, EPS was -$0.58 versus estimates of -$0.57, while revenues of $20.78M topped expectations of $15.24M, with a current ratio of 1.90 and a price/sales of 1.68.
1. Strategic Transformation and Divestiture
MacroGenics is selling its manufacturing operations to Bora Pharmaceuticals to concentrate on antibody-based drug development and reduce operational overhead. This strategic move is designed to preserve capital and extend the company’s cash runway through 2028, supporting ongoing clinical programs without near-term financing.
2. Q1 Financial Results
For the quarter ended May 14, MacroGenics reported an EPS of -$0.58, missing consensus by $0.01 but improving from a -$0.65 loss a year earlier. Revenue climbed to $20.78 million, surpassing analyst estimates of $15.24 million and up from $13.19 million in Q1 of last year.
3. Valuation and Liquidity Metrics
The company’s trailing-12-month Price-to-Earnings ratio stands at -3.75, reflecting ongoing losses, while its Price-to-Sales ratio is 1.68. With a current ratio of 1.90 and a debt-to-equity ratio of 1.72, MacroGenics maintains adequate liquidity to fund operations and clinical milestones.
4. Virtual Forum Participation
President and CEO Eric Risser will participate in a fireside chat at the Stifel 2026 Virtual Targeted Oncology Forum on May 20 at 10:30 a.m. ET. A live webcast will be available in the Investor Relations section of the company’s website, with an archived replay for 30 days.